Company Overview - Ur Energy (URG) is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year decline of 50% [3] - Revenues are anticipated to be $6.83 million, which is an increase of 6.7% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 33.33% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Ur Energy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.50% [12] Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Ur Energy currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat [12] Historical Performance - In the last reported quarter, Ur Energy was expected to post a loss of $0.01 per share but actually reported a loss of -$0.04, resulting in a surprise of -300% [13] - The company has not surpassed consensus EPS estimates in any of the last four quarters [14] Industry Context - In comparison, McEwen (MUX), another player in the Zacks Mining - Miscellaneous industry, is expected to report earnings of $0.31 per share, indicating a year-over-year increase of 875% [18] - McEwen's revenue is projected to be $66.1 million, up 26.5% from the previous year, but it has an Earnings ESP of -44.26% despite a Zacks Rank of 2 (Buy) [19][20]

Core Viewpoint - Adient (ADNT) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Financial Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $0.55 per share, reflecting a year-over-year decrease of 19.1%, while revenues are projected to be $3.63 billion, representing a 2% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 4.76% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that Adient has a positive Earnings ESP of +3.04%, suggesting a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a higher probability of an earnings beat [12]. Historical Performance - In the last reported quarter, Adient was expected to post earnings of $0.47 per share but delivered $0.45, resulting in a surprise of -4.26% [13]. - Over the past four quarters, Adient has surpassed consensus EPS estimates three times [14]. Industry Context - In the broader automotive industry, Magna (MGA) is expected to report earnings of $1.24 per share for the same quarter, reflecting a year-over-year decline of 3.1%, with revenues anticipated at $10.01 billion, down 2.6% from the previous year [18]. - Magna's consensus EPS estimate has been revised up by 1.2% in the last 30 days, and it also has a positive Earnings ESP of +1.34%, indicating a likelihood of beating the consensus EPS estimate [19].

Core Viewpoint - Aeva Technologies, Inc. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and a better-than-expected performance could lead to a stock price increase, while a miss may result in a decline [2]. - The consensus estimate indicates a quarterly loss of $0.45 per share, reflecting an 18.2% year-over-year change, with revenues projected at $2.88 million, representing a 28% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly reassessed their initial estimates during this period [4]. Earnings Surprise Prediction - Aeva Technologies has a positive Earnings ESP of +5.97%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [12]. - However, the stock holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Aeva Technologies was expected to post a loss of $0.44 per share and matched this expectation with an actual loss of -$0.44, resulting in no surprise [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Aeva Technologies does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when deciding on their investment strategy ahead of the earnings release [17].

Core Insights - The market anticipates Adaptive Biotechnologies (ADPT) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025 [1] - The earnings report is expected on November 5, and actual results compared to estimates will significantly influence stock price movements [2] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.16 per share, reflecting a year-over-year change of +27.3% [3] - Expected revenues are projected at $68.02 million, representing a 46.5% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 10.45% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Adaptive Biotechnologies is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +29.03% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - The company has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Adaptive Biotechnologies was expected to post a loss of $0.24 per share but actually reported a loss of -$0.17, resulting in a surprise of +29.17% [13] - The company has successfully beaten consensus EPS estimates in the last four quarters [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Exelixis (EXEL) is also expected to post earnings of $0.68 per share for the quarter ended September 2025, indicating a year-over-year change of +44.7% [18] - Exelixis is projected to have revenues of $589.77 million, up 9.3% from the previous year, with an Earnings ESP of +2.04% [19][20]

Core Viewpoint - The market anticipates Allient (ALNT) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending September 2025, with a consensus EPS estimate of $0.50, reflecting a +61.3% change, and revenues expected to reach $134.68 million, up 7.6% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and the stock may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 5.22% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - Allient's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.00%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - The company has a Zacks Rank of 3, which indicates a neutral outlook, but the positive Earnings ESP enhances the probability of an earnings beat [12]. Historical Performance - In the last reported quarter, Allient exceeded the expected EPS of $0.48 by delivering $0.57, resulting in a surprise of +18.75% [13]. - Over the past four quarters, Allient has consistently beaten consensus EPS estimates [14]. Industry Comparison - nVent Electric (NVT), another player in the Zacks Electronics - Miscellaneous Components industry, is expected to report an EPS of $0.88 for the same quarter, reflecting a +4.8% year-over-year change, with revenues projected at $1.01 billion, up 7.2% [18][19]. - nVent has an Earnings ESP of +1.30% and a Zacks Rank of 2, indicating a strong likelihood of surpassing the consensus EPS estimate [20].

Core Viewpoint - The market anticipates Amcor (AMCR) will report a year-over-year increase in earnings driven by higher revenues, with a focus on how actual results compare to estimates [1][2]. Earnings Expectations - Amcor is expected to report quarterly earnings of $0.19 per share, reflecting an 18.8% increase year-over-year [3]. - Revenues are projected to reach $5.83 billion, representing a significant 73.8% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Amcor is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.93%, suggesting a bearish sentiment among analysts [12]. Earnings Surprise History - In the last reported quarter, Amcor was expected to post earnings of $0.21 per share but delivered only $0.20, resulting in a surprise of -4.76% [13]. - The company has not beaten consensus EPS estimates in any of the last four quarters [14]. Industry Comparison - Sealed Air (SEE), another player in the packaging industry, is expected to report earnings of $0.68 per share, indicating a year-over-year decline of 13.9% [18]. - Sealed Air's revenues are projected at $1.31 billion, down 2.4% from the previous year, but it has a positive Earnings ESP of +1.28% [19][20].

Core Viewpoint - The market anticipates Alight, Inc. (ALIT) to report a year-over-year earnings increase despite lower revenues in its upcoming earnings report for the quarter ended September 2025 [1][3]. Earnings Expectations - Alight is expected to post quarterly earnings of $0.13 per share, reflecting a year-over-year increase of +44.4% [3]. - Revenues are projected to be $535.63 million, which is a decrease of 3.5% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.04% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Alight is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.00% [12]. Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Alight currently holds a Zacks Rank of 4 (Sell), which complicates the prediction of an earnings beat [12]. Historical Performance - Alight has not surpassed consensus EPS estimates in any of the last four quarters, indicating a trend of underperformance [14]. - In the last reported quarter, Alight met the expected earnings of $0.10 per share, resulting in no surprise [13]. Industry Comparison - Another company in the Zacks Internet - Software industry, Pinterest (PINS), is expected to report earnings of $0.41 per share, with a year-over-year change of +2.5% and revenues of $1.05 billion, up 16.6% from the previous year [18]. - Pinterest's consensus EPS estimate has been revised 3.1% lower, leading to an Earnings ESP of -5.68% and a Zacks Rank of 3 (Hold) [19].

Core Viewpoint - Array Technologies, Inc. is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.21 per share, reflecting a year-over-year increase of 23.5% [3]. - Expected revenues are projected at $313.3 million, which is a 35.4% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 14.2% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Array Technologies is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -23.29%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Array Technologies currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Array Technologies was expected to post earnings of $0.21 per share but exceeded expectations with earnings of $0.25, resulting in a surprise of 19.05% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Conclusion - While Array Technologies does not appear to be a compelling earnings-beat candidate, investors should consider other factors when making investment decisions ahead of the earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for ArcBest due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - ArcBest is expected to report quarterly earnings of $1.37 per share, reflecting a year-over-year decrease of 16.5% [3]. - Revenue is projected to be $1.03 billion, down 3.3% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 10.5% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for ArcBest is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.12% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, particularly when combined with a strong Zacks Rank [10]. - ArcBest currently holds a Zacks Rank of 5, making it challenging to predict an earnings beat despite the positive Earnings ESP [12]. Historical Performance - In the last reported quarter, ArcBest was expected to earn $1.48 per share but only achieved $1.36, resulting in a surprise of -8.11% [13]. - Over the past four quarters, ArcBest has only surpassed consensus EPS estimates once [14]. Industry Context - Heartland Express, another player in the Zacks Transportation - Truck industry, is expected to report a loss of $0.11 per share, indicating a year-over-year change of +8.3% [18]. - Heartland Express's revenue is expected to be $213.94 million, down 17.7% from the previous year, with a significant revision of 71.4% lower in the consensus EPS estimate over the last 30 days [19].

Core Insights - Gilead Sciences, Inc. (GILD) is set to report its Q3 2025 results on October 30, with sales and earnings estimates of $7.46 billion and $2.15 per share respectively [1][7] - Earnings estimates for 2025 and 2026 have seen slight declines, with 2025 dropping from $8.09 to $8.07 and 2026 from $8.53 to $8.50 over the past month [1][2] Financial Performance - GILD has a strong earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 11.04% [4][5] - The earnings estimate for Q3 2025 is $2.15 per share, consistent over the past 30 days, while the earnings surprise prediction is currently at -1.34% [8][2] Product Performance - The HIV portfolio, particularly Biktarvy and Descovy, continues to drive top-line growth, with Q3 sales estimates of $3.6 billion for Biktarvy and $629 million for Descovy [9][10] - The recent FDA approval of lenacapavir (Yeztugo) is expected to enhance Gilead's HIV franchise, with projected growth in HIV sales of approximately 3% in 2025 [11][22] Market Dynamics - Gilead's liver disease portfolio, including Livdelzi, is expected to perform well despite some challenges in hepatitis C virus sales [12][14] - Cell Therapy product sales are anticipated to decline due to competitive pressures, with estimates of $476 million for Q3 [15][23] Stock Performance - GILD shares have increased by 27.7% year-to-date, outperforming the industry average of 10.8% [18][19] - The current price/earnings ratio for GILD is 13.98x, higher than its historical mean but lower than the large-cap pharma industry average of 15.57x [21] Strategic Outlook - Gilead's ongoing innovation in the HIV sector and strategic acquisitions are viewed positively, although the Cell Therapy segment faces challenges [22][26] - The company is collaborating with Merck to evaluate a new HIV treatment, with updates expected in 2026 [27]